Dr. Greg Grosicki, a senior research scientist at WHOOP with a PhD in Human Bioenergetics and a passion for exercise physiology, sheds light on GLP-1 medications. He discusses their influence on weight loss and heart health, as well as the critical interplay between these treatments and exercise. The conversation explores the rising popularity of GLP-1 medications for obesity, the challenges in accessibility, and the importance of combining them with lifestyle changes. Greg also highlights how WHOOP's data can enhance our understanding of these therapies.
48:30
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
insights INSIGHT
GLP-1 History
GLP-1 medications, originally for diabetes, now treat obesity and other conditions.
Their discovery dates back to the early 20th century, evolving from intestinal extract research to sophisticated agonists.
question_answer ANECDOTE
WHOOP GLP-1 Study Design
Greg Grosicki's team leveraged WHOOP's behavioral tracker and user surveys to study real-world GLP-1 use.
They compared users taking GLP-1 medications with virtual twins who weren't, enabling unique insights.
insights INSIGHT
Real-World GLP-1 Weight Loss
Real-world data from WHOOP shows 10% weight loss in 12 weeks with GLP-1, exceeding clinical trial results.
90% of WHOOP members achieved clinically significant weight loss (over 5%) in just 12 weeks.
Get the Snipd Podcast app to discover more snips from this episode
Are GLP-1 medications the future of weight loss? On this week’s episode, WHOOP Global Head of Human Performance Principal Scientist, Kristen Holmes, sits down with Dr. Greg Grosicki, WHOOP Senior Research Scientist, to discuss all things GLP-1 and GLP-1 Receptor Agonists (RAs). Dr. Greg Grosicki is a member of the Performance Science team at WHOOP, an accomplished IRONMAN athlete, and holds a PhD in Human Bioenergetics and a Masters Degree in Data Science. Dr. Grosicki’s background focusses on exercise physiology and aims to help people live longer and healthier in order to perform at their peak. Dr. Grosicki recently led a study at WHOOP that looked into the effects of GLP-1 RAs on heart health and responses in health behaviors.
Kristen and Dr. Grosicki discuss Dr. Grosicki’s journey to WHOOP and his research background (1:32), using exercise physiology to help people live longer and healthier (02:52), and how research at WHOOP will help you live better (06:07). Dr. Grosicki dives into the WHOOP GLP-1 study (10:54), GLP-1 medications access (20:48), and what people should expect from a GLP-1RA (23:09). Kristen and Dr. Grosicki break down GLP-1 RAs, their relationships with food addiction (24:30), Hollywood (26:16), and the idea of microdosing drugs like ozempic (27:10). The episode continues, providing an understanding for the importance of studying GLP-1 and using WHOOP as a tool for data collection (28:20), the study’s results (32:56), and identifying research bias (35:55). Kristen and Dr. Grosicki discuss the relationship of GLP-1 and cardiovascular health (39:07), the impact of exercise on cardiovascular health (40:28) and maintaining muscle tissue when using GLP-1RAs (43:42).
WHOOP Podcast